Hepatitis B virus sub-genotype A1 infection is characterized by high replication levels and rapid emergence of drug resistance in HIVPositive adults receiving first-line antiretroviral therapy in Malawi

Clinical Infectious Diseases

Volumn 59, Issue 11, 2014, Pages 1618-1626

  Aoudjane, Samir ^a   Chaponda, Mas ^c   Del Castillo, Antonio Adrián González ^a   O'Connor, Jemma ^b   Noguera, Marc ^d   Beloukas, Apostolos ^c   Hopkins, Mark ^c   Khoo, Saye ^c   Van Oosterhout, Joep J ^e,f   Geretti, Anna Maria ^c  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF LIVERPOOL   (United Kingdom)

^d HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^e UNIVERSITY OF MALAWI   (Malawi)

^f DIGNITAS INTERNATIONAL   (Malawi)

Author keywords

Africa; Lamivudine; Resistance; Sub genotype A1; Viral load

Indexed keywords

HEPATITIS B(E) ANTIBODY; HEPATITIS B(E) ANTIGEN; LAMIVUDINE PLUS NEVIRAPINE PLUS STAVUDINE; VIRUS DNA; VIRUS RNA; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; LAMIVUDINE; NEVIRAPINE; STAVUDINE; STAVUDINE, LAMIVUDINE, NEVIRAPINE DRUG COMBINATION;

ADULT; ANTIVIRAL RESISTANCE; ARTICLE; CLONE; FEMALE; FOLLOW UP; GENE SEQUENCE; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS B VIRUS GENOTYPE A1; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOSPITALIZATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; MAJOR CLINICAL STUDY; MALAWI; MALE; PHYLOGENY; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SEROLOGY; VIRUS CHARACTERIZATION; VIRUS GENOME; VIRUS LOAD; VIRUS MUTATION; VIRUS REPLICATION; CLASSIFICATION; DNA SEQUENCE; DRUG EFFECTS; GENETICS; HIV INFECTIONS; PHYSIOLOGY; RETROSPECTIVE STUDY; VIROLOGY;

ADULT; ANTI-HIV AGENTS; DNA, VIRAL; DRUG RESISTANCE, VIRAL; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HIV INFECTIONS; HUMANS; LAMIVUDINE; MALAWI; MALE; NEVIRAPINE; PHYLOGENY; RETROSPECTIVE STUDIES; SEQUENCE ANALYSIS, DNA; STAVUDINE; VIRAL LOAD; VIRUS REPLICATION;

EID: 84924419957     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciu630     Document Type: Article

References (40)

1. Lacombe K, Rockstroh J. HIV and viral hepatitis coinfections: Advances and challenges. Gut 2012; 61(Suppl. 1): i47-58.
2. Chun HM, Roediger MP, Hullsiek KH, et al. Hepatitis B virus coinfection negatively impacts HIV outcomes in HIV seroconverters. J Infect Dis 2012; 205: 185-93.
3. Gish R, Jia JD, Locarnini S, Zoulim F. Selection of chronic hepatitis B therapy with high barrier to resistance. Lancet Infect Dis 2012; 12: 341-53.
4. Wilkins E, Nelson M, Agarwal K, et al. British HIV Association guidelines for the management of hepatitis viruses in adults infected with HIV 2013. HIV Med 2013; 14(suppl. 4): 1-71.
5. Hoffmann CJ, Thio CL. Clinical implications of HIV and hepatitis B coinfection in Asia and Africa. Lancet Infect Dis 2007; 7: 402-9.
6. Ahmed SD, Cuevas LE, Brabin BJ, et al. Seroprevalence of hepatitis B and C and HIV in Malawian pregnant women. J Infect 1998; 37: 248-51.
7. Sutcliffe S, Taha TE, Kumwenda NI, Taylor E, Liomba GN. HIV-1 prevalence and herpes simplex virus 2, hepatitis C virus, and hepatitis B virus infections among male workers at a sugar estate in Malawi. J Acquir Immune Defic Syndr 2002; 31: 90-7.
8. Moore E, Beadsworth MB, Chaponda M, et al. Favourable one-year ART outcomes in adult Malawians with hepatitis B and C co-infection. J Infect 2010; 61: 155-63.
9. Geretti AM, Patel M, Sarfo FS, et al. Detection of highly prevalent hepatitis B virus coinfection among HIV-seropositive persons in Ghana. J Clin Microbiol 2010; 48: 3223-30.
10. Matthews GV, Manzini P, Hu Z, et al. Impact of lamivudine on HIV and hepatitis B virus-related outcomes in HIV/hepatitis B virus individuals in a randomized clinical trial of antiretroviral therapy in southern Africa. AIDS 2011; 25: 1727-35.
11. Kim NH, Scott J, Cent A, et al. HBV lamivudine resistance among hepatitis B and HIV coinfected patients starting lamivudine, stavudine, and nevirapine in Kenya. J Viral Hepat 2011; 18: e447-452.
12. Kouanfack C, Aghokeng AF, Mondain AM, et al. Lamivudine-resistant HBV infection in HIV-positive patients receiving antiretroviral therapy in a public routine clinic in Cameroon. Antivir Ther 2012; 17: 321-6.
13. Ive P, Macleod W, Mkumla N, et al. Low prevalence of liver disease but regional differences in HBV treatment characteristics mark HIV/HBV co-infection in a South African HIV clinical trial. PLoS One 2013; 8: e74900.
14. Hawkins C, Christian B, Ye J, et al. Prevalence of hepatitis B coinfection and response to antiretroviral therapy among HIV-infected patients in Tanzania. AIDS 2013; 27: 919-27.
15. Day SL, Odem-Davis K, Mandaliya KN, et al. Prevalence, clinical, and virologic outcomes of hepatitis B virus co-infection in HIV-1 positive Kenyan women on antiretroviral therapy. PLoS One 2013; 8: e59346.
16. Hamers RL, Zaaijer HL, Wallis CL, et al. HIV-HBV coinfection in Southern Africa and the effect of lamivudine-versus tenofovir-containing cART on HBV outcomes. J Acquir Immune Defic Syndr 2013; 64: 174-82.
17. Ott JJ, Stevens GA, Groeger J, Wiersma ST. Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine 2012; 30: 2212-9.
18. Chadwick D, Ankcorn M, Sarfo F, et al. Outcomes of starting first-line antiretroviral therapy in hepatitis B virus/HIV-coinfected patients in Ghana. J Antimicrob Chemother 2012; 67: 2939-42.
19. Galluzzo C, Liotta G, Andreotti M, et al. Emergence of lamivudine resistance hepatitis B virus mutations in pregnant women infected with HBV and HIV receiving antiretroviral prophylaxis for the prevention of mother-to-infant transmission in Malawi. J Med Virol 2012; 84: 1553-7.
20. World Health Organization (WHO). 2013 consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. Available at: http://www.who.int/hiv/pub/guidelines/arv2013/en/index.html. Accessed 15 July 2014.
21. Benhamou Y, Bochet M, Thibault V, et al. Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients. Hepatology 1999; 30: 1302-6.
22. Matthews GV, Bartholomeusz A, Locarnini S, et al. Characteristics of drug resistant HBV in an international collaborative study of HIV-HBV-infected individuals on extended lamivudine therapy. AIDS 2006; 20: 863-70.
23. Ramos B, Nunez M, Martin-Carbonero L, et al. Hepatitis B virus genotypes and lamivudine resistance mutations in HIV/hepatitis B virus-coinfected patients. J Acquir Immune Defic Syndr 2007; 44: 557-61.
24. Kramvis A, Kew MC. Molecular characterization of subgenotype A1 (subgroup Aa) of hepatitis B virus. Hepatol Res 2007; 37(Suppl. 1): S27-32.
25. Watson SJ, Welkers MR, Depledge DP, et al. Viral population analysis and minority-variant detection using short read next-generation sequencing. Philos Trans R Soc Lond B Biol Sci 2013; 368: 20120205.
26. Archer J, Baillie G, Watson SJ, Kellam P, Rambaut A, Robertson DL. Analysis of high-depth sequence data for studying viral diversity: a comparison of next generation sequencing platforms using Segminator II. BMC Bioinformatics 2012; 13: 47.
27. Rhee SY, Margeridon-Thermet S, Nguyen MH, et al. Hepatitis B virus reverse transcriptase sequence variant database for sequence analysis and mutation discovery. Antiviral Res 2010; 88: 269-75.
28. Candotti D, Mundy C, Kadewele G, Nkhoma W, Bates I, Allain JP. Serological and molecular screening for viruses in blood donors from Ntcheu, Malawi: High prevalence of HIV-1 subtype C and of markers of hepatitis B and C viruses. J Med Virol 2001; 65: 1-5.
29. Stabinski L, Reynolds SJ, Ocama P, et al. High prevalence of liver fibrosis associated with HIV infection: A study in rural Rakai, Uganda. Antiviral Ther 2011; 16: 405-11.
30. Hawkins C, Agbaji O, Ugoagwu P, et al. Assessment of liver fibrosis by transient elastography in patients with HIV and hepatitis B virus coinfection in Nigeria. Clin Infect Dis 2013; 57: 189-92.
31. Martin NK, Devine A, Eaton JW, et al. Modeling the impact of early antiretroviral therapy for adults coinfected with HIV and hepatitis B or C in South Africa. AIDS 2014; 28(Suppl. 1): S35-46.
32. Di Bisceglie AM, Maskew M, Schulze D, Reyneke A, McNamara L, Firnhaber C. HIV-HBV coinfection among South African patients receiving antiretroviral therapy. Antivir Ther 2010; 15: 499-503.
33. Pallier C, Castera L, Soulier A, et al. Dynamics of hepatitis B virus resistance to lamivudine. J Virol 2006; 80: 643-53.
34. Solmone M, Vincenti D, Prosperi MC, Bruselles A, Ippolito G. Use of massively parallel ultradeep pyrosequencing to characterize the genetic diversity of hepatitis B virus in drug-resistant and drug-naive patients and to detect minor variants in reverse transcriptase and hepatitis B S antigen. J Virol 2009; 83: 1718-26.
35. Margeridon-Thermet S, Svarovskaia ES, Babrzadeh F, et al. Low-level persistence of drug resistance mutations in hepatitis B virus-infected subjects with a past history of lamivudine treatment. Antimicrob Agents Chemother 2013; 57: 343-9.
36. Locarnini S, Zoulim F. Molecular genetics of HBV infection. Antivir Ther 2010; 15(Suppl. 3): 3-14.
37. Karatayli E, Karayalcin S, Karaaslan H, et al. A novel mutation pattern emerging during lamivudine treatment shows cross-resistance to adefovir dipivoxil treatment. Antivir Ther 2007; 12: 761-8.
38. Baran B, Soyer OM, Ormeci AC, et al. Efficacy of tenofovir in patients with lamivudine failure is not different from that in nucleoside/nucleotide analogue-naive patients with chronic hepatitis B. Antimicrob Agents Chemother 2013; 57: 1790-6.
39. Wiersma ST, McMahon B, Pawlotsky JM, et al. World Health Organization Department of Immunization, Vaccines and Biologicals. Treatment of chronic hepatitis B virus infection in resource-constrained settings: Expert panel consensus. Liver Int 2011; 31: 755-61.
40. Lemoine M, Thursz M, Njie R, Dusheiko GM. Forgotten, not neglected: Viral hepatitis in resource-limited settings, recall for action. Liver Int 2014; 34: 12-5.